Pre-treatment double- or triple-positive tumor markers are predictive of a poor outcome for patients undergoing radiofrequency ablation for hepatocellular carcinoma
Purposes We evaluated the therapeutic effect of radiofrequency ablation (RFA) on hepatocellular carcinoma (HCC) according to the number of positive tumor markers. Methods The subjects of this study were 160 patients who underwent percutaneous and surgical RFA for HCC. Patients were divided into nega...
Gespeichert in:
| Veröffentlicht in: | Surgery today (Tokyo, Japan) Japan), 2017-03, Vol.47 (3), p.375-384 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 384 |
|---|---|
| container_issue | 3 |
| container_start_page | 375 |
| container_title | Surgery today (Tokyo, Japan) |
| container_volume | 47 |
| creator | Nitta, Hidetoshi Nakagawa, Shigeki Kaida, Takayoshi Arima, Kota Higashi, Takaaki Taki, Katsunobu Okabe, Hirohisa Hayashi, Hiromitsu Hashimoto, Daisuke Chikamoto, Akira Ishiko, Takatoshi Beppu, Toru Baba, Hideo |
| description | Purposes
We evaluated the therapeutic effect of radiofrequency ablation (RFA) on hepatocellular carcinoma (HCC) according to the number of positive tumor markers.
Methods
The subjects of this study were 160 patients who underwent percutaneous and surgical RFA for HCC. Patients were divided into negative (
n
= 51), single- (
n
= 69), double- (
n
= 31), and triple-positive (
n
= 9) tumor marker groups according to the pre-treatment expression of these markers. We looked for any relationships among clinical parameters, outcomes, and tumor markers.
Results
The 3-year recurrence-free and overall survival rates of the negative, single-, double-, and triple-positive groups were 30, 19, 16, and 11 % (
P
= 0.02), and 94, 88, 67, and 37 % (
P
|
| doi_str_mv | 10.1007/s00595-016-1385-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1859733219</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1859733219</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-4abf047c013865a87f54d16e9c368da83dca110971f82d5411d31aaea91300303</originalsourceid><addsrcrecordid>eNp9kU1uFDEQhS1ERIbAAdggL9kYXG333xJFBJAiwSJZWx67enDobjdlGyn3yUHxZAJLVi65vvdUVY-xNyDfg5T9hyRlO7ZCQidADa3onrEdaNWJZgD1nO3kqEFAM8I5e5nSnZSNHqR8wc6bvtVj33c79vCdUGRCmxdcM_ex7GcUPBLPFLZabjGFHH4jz2Wpv4uln0iJW0K-EfrgHptx4pZvsQKxZBcX5FOtN5tDdU28rB7pEMN64GR9iBPhr4Kru-d2P1coro_8D6yK6HCey2yJO0surHGxr9jZZOeEr5_eC3Z79enm8ou4_vb56-XHa-G00llou5-k7p2sx-haO_RTqz10ODrVDd4OyjsLIMcepqHxrQbwCqxFO4KSUkl1wd6dfDeKdb6UzRLScRy7YizJwNCOvVINjBWFE-oopkQ4mY1CPc69AWmO4ZhTOKaGY47hmK5q3j7Zl_2C_p_ibxoVaE5Aqq31gGTuYqG1rvwf1z_y-J5L</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1859733219</pqid></control><display><type>article</type><title>Pre-treatment double- or triple-positive tumor markers are predictive of a poor outcome for patients undergoing radiofrequency ablation for hepatocellular carcinoma</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Nitta, Hidetoshi ; Nakagawa, Shigeki ; Kaida, Takayoshi ; Arima, Kota ; Higashi, Takaaki ; Taki, Katsunobu ; Okabe, Hirohisa ; Hayashi, Hiromitsu ; Hashimoto, Daisuke ; Chikamoto, Akira ; Ishiko, Takatoshi ; Beppu, Toru ; Baba, Hideo</creator><creatorcontrib>Nitta, Hidetoshi ; Nakagawa, Shigeki ; Kaida, Takayoshi ; Arima, Kota ; Higashi, Takaaki ; Taki, Katsunobu ; Okabe, Hirohisa ; Hayashi, Hiromitsu ; Hashimoto, Daisuke ; Chikamoto, Akira ; Ishiko, Takatoshi ; Beppu, Toru ; Baba, Hideo</creatorcontrib><description>Purposes
We evaluated the therapeutic effect of radiofrequency ablation (RFA) on hepatocellular carcinoma (HCC) according to the number of positive tumor markers.
Methods
The subjects of this study were 160 patients who underwent percutaneous and surgical RFA for HCC. Patients were divided into negative (
n
= 51), single- (
n
= 69), double- (
n
= 31), and triple-positive (
n
= 9) tumor marker groups according to the pre-treatment expression of these markers. We looked for any relationships among clinical parameters, outcomes, and tumor markers.
Results
The 3-year recurrence-free and overall survival rates of the negative, single-, double-, and triple-positive groups were 30, 19, 16, and 11 % (
P
= 0.02), and 94, 88, 67, and 37 % (
P
< 0.001), respectively. The 2-year local recurrence rates were 6.5, 0, 41.2, and 61.9 %, respectively (
P
< 0.001). Multivariate analysis revealed that a double- or triple-positive pre-treatment tumor marker profile was independently associated with local recurrence [hazard ratio (HR) 5.48, 95 % confidence interval (CI) 2.44–12.33,
P
< 0.001] and overall survival (HR 4.21, 95 % CI 1.89–9.37,
P
< 0.001).
Conclusion
RFA may not be suitable for patients with HCC who have pre-treatment expression of ≥two of these tumor markers.</description><identifier>ISSN: 0941-1291</identifier><identifier>EISSN: 1436-2813</identifier><identifier>DOI: 10.1007/s00595-016-1385-6</identifier><identifier>PMID: 27549776</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Adult ; Aged ; Aged, 80 and over ; alpha-Fetoproteins - analysis ; Biomarkers - analysis ; Biomarkers, Tumor - blood ; Carcinoma, Hepatocellular - diagnosis ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - surgery ; Catheter Ablation - mortality ; Female ; Humans ; Liver Neoplasms - diagnosis ; Liver Neoplasms - mortality ; Liver Neoplasms - surgery ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Recurrence, Local - epidemiology ; Original Article ; Predictive Value of Tests ; Protein Precursors - analysis ; Prothrombin - analysis ; Surgery ; Surgical Oncology ; Survival Rate ; Treatment Outcome</subject><ispartof>Surgery today (Tokyo, Japan), 2017-03, Vol.47 (3), p.375-384</ispartof><rights>Springer Japan 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-4abf047c013865a87f54d16e9c368da83dca110971f82d5411d31aaea91300303</citedby><cites>FETCH-LOGICAL-c434t-4abf047c013865a87f54d16e9c368da83dca110971f82d5411d31aaea91300303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00595-016-1385-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00595-016-1385-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27549776$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nitta, Hidetoshi</creatorcontrib><creatorcontrib>Nakagawa, Shigeki</creatorcontrib><creatorcontrib>Kaida, Takayoshi</creatorcontrib><creatorcontrib>Arima, Kota</creatorcontrib><creatorcontrib>Higashi, Takaaki</creatorcontrib><creatorcontrib>Taki, Katsunobu</creatorcontrib><creatorcontrib>Okabe, Hirohisa</creatorcontrib><creatorcontrib>Hayashi, Hiromitsu</creatorcontrib><creatorcontrib>Hashimoto, Daisuke</creatorcontrib><creatorcontrib>Chikamoto, Akira</creatorcontrib><creatorcontrib>Ishiko, Takatoshi</creatorcontrib><creatorcontrib>Beppu, Toru</creatorcontrib><creatorcontrib>Baba, Hideo</creatorcontrib><title>Pre-treatment double- or triple-positive tumor markers are predictive of a poor outcome for patients undergoing radiofrequency ablation for hepatocellular carcinoma</title><title>Surgery today (Tokyo, Japan)</title><addtitle>Surg Today</addtitle><addtitle>Surg Today</addtitle><description>Purposes
We evaluated the therapeutic effect of radiofrequency ablation (RFA) on hepatocellular carcinoma (HCC) according to the number of positive tumor markers.
Methods
The subjects of this study were 160 patients who underwent percutaneous and surgical RFA for HCC. Patients were divided into negative (
n
= 51), single- (
n
= 69), double- (
n
= 31), and triple-positive (
n
= 9) tumor marker groups according to the pre-treatment expression of these markers. We looked for any relationships among clinical parameters, outcomes, and tumor markers.
Results
The 3-year recurrence-free and overall survival rates of the negative, single-, double-, and triple-positive groups were 30, 19, 16, and 11 % (
P
= 0.02), and 94, 88, 67, and 37 % (
P
< 0.001), respectively. The 2-year local recurrence rates were 6.5, 0, 41.2, and 61.9 %, respectively (
P
< 0.001). Multivariate analysis revealed that a double- or triple-positive pre-treatment tumor marker profile was independently associated with local recurrence [hazard ratio (HR) 5.48, 95 % confidence interval (CI) 2.44–12.33,
P
< 0.001] and overall survival (HR 4.21, 95 % CI 1.89–9.37,
P
< 0.001).
Conclusion
RFA may not be suitable for patients with HCC who have pre-treatment expression of ≥two of these tumor markers.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>alpha-Fetoproteins - analysis</subject><subject>Biomarkers - analysis</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoma, Hepatocellular - diagnosis</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Catheter Ablation - mortality</subject><subject>Female</subject><subject>Humans</subject><subject>Liver Neoplasms - diagnosis</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - surgery</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - epidemiology</subject><subject>Original Article</subject><subject>Predictive Value of Tests</subject><subject>Protein Precursors - analysis</subject><subject>Prothrombin - analysis</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>0941-1291</issn><issn>1436-2813</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1uFDEQhS1ERIbAAdggL9kYXG333xJFBJAiwSJZWx67enDobjdlGyn3yUHxZAJLVi65vvdUVY-xNyDfg5T9hyRlO7ZCQidADa3onrEdaNWJZgD1nO3kqEFAM8I5e5nSnZSNHqR8wc6bvtVj33c79vCdUGRCmxdcM_ex7GcUPBLPFLZabjGFHH4jz2Wpv4uln0iJW0K-EfrgHptx4pZvsQKxZBcX5FOtN5tDdU28rB7pEMN64GR9iBPhr4Kru-d2P1coro_8D6yK6HCey2yJO0surHGxr9jZZOeEr5_eC3Z79enm8ou4_vb56-XHa-G00llou5-k7p2sx-haO_RTqz10ODrVDd4OyjsLIMcepqHxrQbwCqxFO4KSUkl1wd6dfDeKdb6UzRLScRy7YizJwNCOvVINjBWFE-oopkQ4mY1CPc69AWmO4ZhTOKaGY47hmK5q3j7Zl_2C_p_ibxoVaE5Aqq31gGTuYqG1rvwf1z_y-J5L</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Nitta, Hidetoshi</creator><creator>Nakagawa, Shigeki</creator><creator>Kaida, Takayoshi</creator><creator>Arima, Kota</creator><creator>Higashi, Takaaki</creator><creator>Taki, Katsunobu</creator><creator>Okabe, Hirohisa</creator><creator>Hayashi, Hiromitsu</creator><creator>Hashimoto, Daisuke</creator><creator>Chikamoto, Akira</creator><creator>Ishiko, Takatoshi</creator><creator>Beppu, Toru</creator><creator>Baba, Hideo</creator><general>Springer Japan</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170301</creationdate><title>Pre-treatment double- or triple-positive tumor markers are predictive of a poor outcome for patients undergoing radiofrequency ablation for hepatocellular carcinoma</title><author>Nitta, Hidetoshi ; Nakagawa, Shigeki ; Kaida, Takayoshi ; Arima, Kota ; Higashi, Takaaki ; Taki, Katsunobu ; Okabe, Hirohisa ; Hayashi, Hiromitsu ; Hashimoto, Daisuke ; Chikamoto, Akira ; Ishiko, Takatoshi ; Beppu, Toru ; Baba, Hideo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-4abf047c013865a87f54d16e9c368da83dca110971f82d5411d31aaea91300303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>alpha-Fetoproteins - analysis</topic><topic>Biomarkers - analysis</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoma, Hepatocellular - diagnosis</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Catheter Ablation - mortality</topic><topic>Female</topic><topic>Humans</topic><topic>Liver Neoplasms - diagnosis</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - surgery</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - epidemiology</topic><topic>Original Article</topic><topic>Predictive Value of Tests</topic><topic>Protein Precursors - analysis</topic><topic>Prothrombin - analysis</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nitta, Hidetoshi</creatorcontrib><creatorcontrib>Nakagawa, Shigeki</creatorcontrib><creatorcontrib>Kaida, Takayoshi</creatorcontrib><creatorcontrib>Arima, Kota</creatorcontrib><creatorcontrib>Higashi, Takaaki</creatorcontrib><creatorcontrib>Taki, Katsunobu</creatorcontrib><creatorcontrib>Okabe, Hirohisa</creatorcontrib><creatorcontrib>Hayashi, Hiromitsu</creatorcontrib><creatorcontrib>Hashimoto, Daisuke</creatorcontrib><creatorcontrib>Chikamoto, Akira</creatorcontrib><creatorcontrib>Ishiko, Takatoshi</creatorcontrib><creatorcontrib>Beppu, Toru</creatorcontrib><creatorcontrib>Baba, Hideo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Surgery today (Tokyo, Japan)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nitta, Hidetoshi</au><au>Nakagawa, Shigeki</au><au>Kaida, Takayoshi</au><au>Arima, Kota</au><au>Higashi, Takaaki</au><au>Taki, Katsunobu</au><au>Okabe, Hirohisa</au><au>Hayashi, Hiromitsu</au><au>Hashimoto, Daisuke</au><au>Chikamoto, Akira</au><au>Ishiko, Takatoshi</au><au>Beppu, Toru</au><au>Baba, Hideo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pre-treatment double- or triple-positive tumor markers are predictive of a poor outcome for patients undergoing radiofrequency ablation for hepatocellular carcinoma</atitle><jtitle>Surgery today (Tokyo, Japan)</jtitle><stitle>Surg Today</stitle><addtitle>Surg Today</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>47</volume><issue>3</issue><spage>375</spage><epage>384</epage><pages>375-384</pages><issn>0941-1291</issn><eissn>1436-2813</eissn><abstract>Purposes
We evaluated the therapeutic effect of radiofrequency ablation (RFA) on hepatocellular carcinoma (HCC) according to the number of positive tumor markers.
Methods
The subjects of this study were 160 patients who underwent percutaneous and surgical RFA for HCC. Patients were divided into negative (
n
= 51), single- (
n
= 69), double- (
n
= 31), and triple-positive (
n
= 9) tumor marker groups according to the pre-treatment expression of these markers. We looked for any relationships among clinical parameters, outcomes, and tumor markers.
Results
The 3-year recurrence-free and overall survival rates of the negative, single-, double-, and triple-positive groups were 30, 19, 16, and 11 % (
P
= 0.02), and 94, 88, 67, and 37 % (
P
< 0.001), respectively. The 2-year local recurrence rates were 6.5, 0, 41.2, and 61.9 %, respectively (
P
< 0.001). Multivariate analysis revealed that a double- or triple-positive pre-treatment tumor marker profile was independently associated with local recurrence [hazard ratio (HR) 5.48, 95 % confidence interval (CI) 2.44–12.33,
P
< 0.001] and overall survival (HR 4.21, 95 % CI 1.89–9.37,
P
< 0.001).
Conclusion
RFA may not be suitable for patients with HCC who have pre-treatment expression of ≥two of these tumor markers.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>27549776</pmid><doi>10.1007/s00595-016-1385-6</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-1291 |
| ispartof | Surgery today (Tokyo, Japan), 2017-03, Vol.47 (3), p.375-384 |
| issn | 0941-1291 1436-2813 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1859733219 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Aged, 80 and over alpha-Fetoproteins - analysis Biomarkers - analysis Biomarkers, Tumor - blood Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - surgery Catheter Ablation - mortality Female Humans Liver Neoplasms - diagnosis Liver Neoplasms - mortality Liver Neoplasms - surgery Male Medicine Medicine & Public Health Middle Aged Neoplasm Recurrence, Local - epidemiology Original Article Predictive Value of Tests Protein Precursors - analysis Prothrombin - analysis Surgery Surgical Oncology Survival Rate Treatment Outcome |
| title | Pre-treatment double- or triple-positive tumor markers are predictive of a poor outcome for patients undergoing radiofrequency ablation for hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T19%3A37%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pre-treatment%20double-%20or%20triple-positive%20tumor%20markers%20are%20predictive%20of%20a%20poor%20outcome%20for%20patients%20undergoing%20radiofrequency%20ablation%20for%20hepatocellular%20carcinoma&rft.jtitle=Surgery%20today%20(Tokyo,%20Japan)&rft.au=Nitta,%20Hidetoshi&rft.date=2017-03-01&rft.volume=47&rft.issue=3&rft.spage=375&rft.epage=384&rft.pages=375-384&rft.issn=0941-1291&rft.eissn=1436-2813&rft_id=info:doi/10.1007/s00595-016-1385-6&rft_dat=%3Cproquest_cross%3E1859733219%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1859733219&rft_id=info:pmid/27549776&rfr_iscdi=true |